Skip to main content
Journal cover image

Treatment preference for opioid use disorder among people who are incarcerated.

Publication ,  Journal Article
Kaplowitz, E; Truong, AQ; Berk, J; Martin, RA; Clarke, JG; Wieck, M; Rich, J; Brinkley-Rubinstein, L
Published in: J Subst Abuse Treat
June 2022

INTRODUCTION: The devastating overdose crisis remains a leading cause of death in the United States, especially among individuals involved in the criminal legal system. Currently, three classes (opioid agonist, partial agonist-antagonist, and antagonist) of FDA-approved medications for opioid use disorder (MOUD) exist, yet few correctional settings offer any medication treatment for people who are incarcerated. Facilities that do often provide only one medication. METHODS: We conducted 40 semi-structured qualitative interviews with individuals receiving MOUD incarcerated at the Rhode Island Department of Corrections. RESULTS: Results from this study indicate that people who are incarcerated have preferences for certain types of MOUD. Individuals' preferences were influenced by medication side effects, route of administration, delivery in the community, and stigma. CONCLUSION: MOUD programs in the community and in correctional settings should use a patient-centered approach that allows choice of medication by offering all FDA-approved MOUD treatment options.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Subst Abuse Treat

DOI

EISSN

1873-6483

Publication Date

June 2022

Volume

137

Start / End Page

108690

Location

United States

Related Subject Headings

  • United States
  • Substance Abuse
  • Social Stigma
  • Prisoners
  • Opioid-Related Disorders
  • Opiate Substitution Treatment
  • Humans
  • Drug Overdose
  • Buprenorphine
  • Analgesics, Opioid
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kaplowitz, E., Truong, A. Q., Berk, J., Martin, R. A., Clarke, J. G., Wieck, M., … Brinkley-Rubinstein, L. (2022). Treatment preference for opioid use disorder among people who are incarcerated. J Subst Abuse Treat, 137, 108690. https://doi.org/10.1016/j.jsat.2021.108690
Kaplowitz, Eliana, Ashley Q. Truong, Justin Berk, Rosemarie A. Martin, Jennifer G. Clarke, Morgan Wieck, Josiah Rich, and Lauren Brinkley-Rubinstein. “Treatment preference for opioid use disorder among people who are incarcerated.J Subst Abuse Treat 137 (June 2022): 108690. https://doi.org/10.1016/j.jsat.2021.108690.
Kaplowitz E, Truong AQ, Berk J, Martin RA, Clarke JG, Wieck M, et al. Treatment preference for opioid use disorder among people who are incarcerated. J Subst Abuse Treat. 2022 Jun;137:108690.
Kaplowitz, Eliana, et al. “Treatment preference for opioid use disorder among people who are incarcerated.J Subst Abuse Treat, vol. 137, June 2022, p. 108690. Pubmed, doi:10.1016/j.jsat.2021.108690.
Kaplowitz E, Truong AQ, Berk J, Martin RA, Clarke JG, Wieck M, Rich J, Brinkley-Rubinstein L. Treatment preference for opioid use disorder among people who are incarcerated. J Subst Abuse Treat. 2022 Jun;137:108690.
Journal cover image

Published In

J Subst Abuse Treat

DOI

EISSN

1873-6483

Publication Date

June 2022

Volume

137

Start / End Page

108690

Location

United States

Related Subject Headings

  • United States
  • Substance Abuse
  • Social Stigma
  • Prisoners
  • Opioid-Related Disorders
  • Opiate Substitution Treatment
  • Humans
  • Drug Overdose
  • Buprenorphine
  • Analgesics, Opioid